
In a recent note, Zacks Small-Cap Research (Zacks SCR) laid out why it believes Lexaria Bioscience, a micro-cap company that is working on making popular weight-loss injections like Wegovy and Zepbound into pills using its patented technology, should be valued at $8 per share — 222% above the current market…